ARR screening using IDS-iSYS Aldosterone and Direct Renin: effects of medication in essential and renovascular hypertension, Cushing’s syndrome and primary aldosteronism

R. Sustarcic1, C. Lonati2, J. Manolopoulos3, M. Reincke1, M. Billingmaier1, A. Morganti2

1Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Munich, Germany
2Department of Internal Medicine and Hypertension Center, San Giuseppe Hospital, University of Milan, Milan, Italy
3Immunodiagnostic Systems, Boldon, UK

Background
Primary aldosteronism (PA), a more frequent form of secondary hypertension than previously thought, is commonly produced either by an aldosterone-producing adenoma or by adrenal hyperplasia. PA is characterized by elevated plasma levels of aldosterone and suppressed renin secretion. Calculation of the aldosterone-to-renin ratio (ARR) was introduced 30 years ago as a convenient screening test for the diagnosis of PA due to the unique and characteristic profile of aldosterone and renin levels observed in this disorder. The relationship between the ARR and aldosterone values can be used to easily depict subgroup differentiation of primary and secondary hyper- and hypoaldosteronism as well as normal subjects (Fig. 1; McKenna et al., 1991). By assessing the levels of plasma aldosterone in relation to ARR, a variety of disorders of the renin-angiotensin-aldosterone axis can be described.

Identifying hypertensive patients with PA is crucial for optimizing their treatment. Various medications used to treat hypertension are known to alter levels of aldosterone and renin, thus affecting the ARR. As withdrawing all medication before screening is often unrealistic, we aimed to determine the degree of interference of some commonly used agents on the ARR using assays on the automated IDS-iSYS platform (Boldon, UK).

Methods
In order to depict the distribution of ARR values across various disease areas and to show the relationship to the levels of plasma aldosterone, we measured ARR in a total of 722 samples. These included samples from healthy individuals (262) as well as from patients with essential hypertension (282), renovascular hypertension (16), Cushing’s syndrome (3) and PA (159).

To evaluate how hypertension medication affects the ARR, we focused on a cohort of 65 patients (32 males, 33 females) with essential hypertension, renovascular hypertension, PA or Cushing’s syndrome (Fig. 2). Fifty-seven of the patients were taking anti-hypertensive medication at the time of screening. Mean age was 59±17 years. For the majority of patients, both supine and standing samples were available.

IDS-iSYS Aldosterone and Direct Renin assays were used for all aldosterone and renin measurements. A previously determined cut-off of greater than 1.1 ng/dL/µL was used to indicate the presence of PA.

Results
The relationship between ARR and plasma aldosterone in healthy individuals as well as in patients with different types of hypertension is depicted in Fig. 3.

ARR values of samples from the cohort, in which effect of hypertension medication was evaluated, are graphed in Fig. 4. In patients with PA, 15 out of 19 samples had an ARR value above the cut-off. All samples from patients with renovascular hypertension (n=16) and Cushing’s (n=3) displayed a negative ARR regardless of medication. Importantly, there is a clear discrimination between PA and renovascular hypertension, which is the other major form of secondary hypertension. In samples from patients with essential hypertension (n=78), 20 false positive ARRs were measured, 16 of which were standing samples. Seventeen of the 20 false positives were from patients taking β-blockers, whereas two were from patients not taking any hypertension medication.

Conclusions
The theoretical classification of patients based on the relationship between ARR and plasma aldosterone did not accurately predict the type of hypertension in our samples. The high overlap between the groups presented in Fig. 3 could be partly due to effects of hypertension medication.

Interrupting hypertension medication for ARR screening gives the most accurate but is not ideal for the patient. We observed a false positive outcome in 26% of samples from patients with essential hypertension, which was mostly associated with β-blockers and/or standing sampling position. Therefore, it may not be necessary to withdraw all drugs for the ARR screening as long as the effects are taken into account when interpreting results.

Figure 1: Theoretical classification of patients based on the relationship between ARR and plasma aldosterone values. Modified from McKenna et al., 1991.

Figure 2: Characteristics of the cohort for determining effects of medication on ARR.

Figure 3: Relationship between ARR and plasma aldosterone values in healthy individuals and different hypertensive patient groups.

Figure 4: ARR in samples from different groups of hypertensive patients, most of whom are on hypertension medication. Dashed line marks the 1.1 ng/dL/µL cut-off for PA.

Figure 5: Effects of medication on false positives and negatives.

PA vs. non-PA

PA: ARR >1.1 ng/dL/µL/mL

non-PA: ARR <1.1 ng/dL/µL/mL

Correct diagnosis for 15/19 PA patients ≈ 4 false negatives

No false positives for Cushing’s (3) or renovascular hypertension (16) patients

20 false positives for essential hypertension patients (78)

16/20 sampled in standing position

17/20 on β-blockers

2/20 not on any medication (both standing)

References:
McKenna TJ, Sequeira SJ, Hofferfern A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991 73(5):952-957

Abbreviations:
PA, primary aldosteronism
ARR, aldosterone to renin ratio